Randomised clinical trial: daily pantoprazole magnesium 40 mg vs. esomeprazole 40 mg for gastro-oesophageal reflux disease, assessed by endoscopy and symptoms

Imagem de Miniatura
Arquivos
art_MORAES-FILHO_Randomised_clinical_trial_daily_pantoprazole_magnesium_40_mg_2014.PDF (261.64 KB)
Citações na Scopus
11
Tipo de produção
article
Data de publicação
2014
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
WILEY-BLACKWELL
Autores
PEDROSO, M.
QUIGLEY, E. M. M.
Citação
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, v.39, n.1, p.47-56, 2014
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
BackgroundPantoprazole magnesium (pantoprazole-Mg) may display extended inhibition of the proton pump with the potential for improved clinical efficacy in gastro-oesophageal reflux disease (GERD). AimTo compare the efficacy of pantoprazole-Mg and esomeprazole in GERD. MethodsGastro-oesophageal reflux disease (Los Angeles grades A-D) patients were randomised to 4weeks of treatment with pantoprazole-Mg (n=290) or esomeprazole (n=288), both 40mg once daily, in this multicentre (14 Brazilian sites in 9 cities), double-blind study, with an additional 4weeks' treatment in nonresponding patients. Severity of oesophagitis (at endoscopy) and GERD-related symptoms (ReQuest-GI) were assessed. The primary end point was the proportion of patients in complete remission (ReQuest-GI score <1.73 plus endoscopic healing) at week 4. ResultsComplete remission occurred in 61% of patients in each treatment group at 4weeks (primary endpoint) and in 81% and 79% of patients in the pantoprazole-Mg and esomeprazole groups at 8weeks, with no significant differences. Mucosal healing rates were high and not significantly different. At 8weeks, symptom relief with pantoprazole-Mg was significantly greater than that with esomeprazole (91.6% vs. 86.0%, P=0.0370) because of continued improvement in symptoms with pantoprazole-Mg from week 4 to week 8 (P=0.0206). ConclusionsPantoprazole-Mg 40mg was at least as effective as esomeprazole 40mg for complete remission and the mucosal healing rate was high. Symptom relief with pantoprazole-Mg continued to improve from 4 to 8weeks and was greater than that with esomeprazole at week 8, suggesting an extended period of treatment effect (ClinicalTrials.gov identifier: NCT01132638).
Palavras-chave
URI
https://observatorio.fm.usp.br/handle/OPI/5388
Referências
  1. Bardhan KD, 2007, DIGESTION, V75, P87, DOI 10.1159/000101020
  2. Bardhan KD, 2007, ALIMENT PHARM THERAP, V25, P1461, DOI 10.1111/j.1365-2036.2007.03337.x
  3. Bate CM, 1997, ALIMENT PHARM THERAP, V11, P755, DOI 10.1046/j.1365-2036.1997.00198.x
  4. Becher A, 2011, ALIMENT PHARM THER, V34, P618, DOI 10.1111/j.1365-2036.2011.04774.x
  5. Castell DO, 2002, AM J GASTROENTEROL, V97, P575
  6. Chiba N, 1997, GASTROENTEROLOGY, V112, P1798, DOI 10.1053/gast.1997.v112.pm9178669
  7. Gillessen A, 2004, J CLIN GASTROENTEROL, V38, P332, DOI 10.1097/00004836-200404000-00007
  8. Hansen AN, 2006, INT J CLIN PRACT, V60, P15, DOI 10.1111/j.1368-5031.2005.00768.x
  9. Hein J, 2011, CLIN DRUG INVEST, V31, P655, DOI 10.2165/11590270-000000000-00000
  10. Irvine EJ, 2004, GUT, V53, P35, DOI 10.1136/gut.2003.034314
  11. Kahrilas PJ, 2000, ALIMENT PHARM THERAP, V14, P1249, DOI 10.1046/j.1365-2036.2000.00856.x
  12. Kandulski A, 2012, NAT REV GASTRO HEPAT, V9, P15, DOI 10.1038/nrgastro.2011.210
  13. Katashima M, 1998, EUR J DRUG METAB PH, V23, P19
  14. Labenz J, 2005, ALIMENT PHARM THERAP, V21, P739, DOI 10.1111/j.1365-2036.2005.02368.x
  15. Lopez-Alvarenga JC, 2011, J NEUROGASTROENTEROL, V17, P381, DOI 10.5056/jnm.2011.17.4.381
  16. McGuigan J, 2007, AM J GASTROENTEROL, V102, pS443
  17. McKeage K, 2008, DRUGS, V68, P1571, DOI 10.2165/00003495-200868110-00009
  18. Monnikes H, 2004, DIGESTION, V69, P238, DOI 10.1159/000079708
  19. Moraes-Filho Joaquim Prado P., 2005, Arquivos de Gastroenterologia, V42, P122, DOI 10.1590/S0004-28032005000200011
  20. Morales-Arambula M, 2009, GASTROENTEROLOGY, V136, pA428
  21. Richter JE, 2001, AM J GASTROENTEROL, V96, P656
  22. Ronkainen J, 2006, ALIMENT PHARM THERAP, V23, P1725, DOI 10.1111/j.1365-2036.2006.02952.x
  23. Sachs G, 2006, ALIMENT PHARM THERAP, V23, P2, DOI 10.1111/j.1365-2036.2006.02943.x
  24. Scholten T, 2003, ALIMENT PHARM THERAP, V18, P587, DOI 10.1046/j.1365-2036.2003.01745.x
  25. Shaker R, 2003, AM J GASTROENTEROL, V98, P1487, DOI 10.1016/S0002-9270(03)00360-5
  26. Shin JM, 2013, J NEUROGASTROENTEROL, V19, P25, DOI 10.5056/jnm.2013.19.1.25
  27. Tack J, 2012, ALIMENT PHARM THER, V35, P1257, DOI 10.1111/j.1365-2036.2012.05086.x
  28. Thomson ABR, 2007, CLIN DRUG INVEST, V27, P663, DOI 10.2165/00044011-200727100-00001
  29. van Zanten SV, 2012, CAN J GASTROENTEROL, V26, P196

Coleções
Artigos e Materiais de Revistas Científicas - FM/MGT